The drugmaker Dyax (NYSE:DYAX) said it established an exclusive distribution agreement with AmerisourceBergen Specialty Group Inc. for its experimental drug Kalbitor. Dyax's (NYSE:DYAX) mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs while delivering outstanding value to patients and stockholders. At the core of their success is their powerful and proprietary drug discovery technology, phage display. This technology provides them with a unique advantage of being able to identify and develop their own clinical leads to fuel their internal pipeline. They also leverage phage display into licenses and collaborations with companies and researchers interested in furthering their own pipelines.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Dyax provides access to its phage display libraries in various types of licenses and collaborations under the Licensing and Funded Research Program. Under the LFRP, they maintain more than 70 licenses and collaborations with various research, biotechnology and pharmaceutical companies. These licensees have advanced into clinical development numerous drug candidates identified using our phage display libraries. Their licensee pipeline currently includes one approved product and 16 clinical-stage drug candidates. As one of the nation's largest pharmaceutical services providers, AmerisourceBergen works with manufacturers of branded pharmaceuticals, generic pharmaceuticals, biotech and specialty drugs, over-the-counter remedies, and health and beauty aids, leveraging our scale to provide our customers with the best value. They service independent retail pharmacies, national and regional chains, hospitals, clinics, pharmacy benefit managers, prescription mail order facilities, physician offices, and long-term care facilities
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
